MacroGenics Presents Flotetuzumab Data in Patients with Primary Induction Failure and Early Relapsed Acute Myeloid Leukemia at the 2019 ASH Annual Meeting
December 09, 2019 15:05 ET
|
MacroGenics, Inc.
Rockville, MD, Dec. 09, 2019 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal...
MacroGenics to Participate in the Evercore ISI HealthCONx Conference
December 02, 2019 07:30 ET
|
MacroGenics, Inc.
Rockville, MD, Dec. 02, 2019 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal...
MacroGenics to Participate in Upcoming Investor Conferences
November 07, 2019 16:45 ET
|
MacroGenics, Inc.
Rockville, MD, Nov. 07, 2019 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal...
MacroGenics Provides Update on Corporate Progress and Third Quarter 2019 Financial Results
November 06, 2019 16:01 ET
|
MacroGenics, Inc.
ROCKVILLE, Md., Nov. 06, 2019 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal...
MacroGenics Announces Flotetuzumab Presentations at the ASH Annual Meeting 2019
November 06, 2019 09:12 ET
|
MacroGenics, Inc.
ROCKVILLE, MD, Nov. 06, 2019 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal...
MacroGenics Announces Date of Third Quarter 2019 Financial Results Conference Call
October 30, 2019 16:05 ET
|
MacroGenics, Inc.
Rockville, MD, Oct. 30, 2019 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal...
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against MacroGenics, ViewRay, Cadence Bancorp, and ProPetro and Encourages Investors to Contact the Firm
October 30, 2019 16:00 ET
|
Bragar Eagel & Squire
NEW YORK, Oct. 30, 2019 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder law firm, reminds investors that class action lawsuits have been commenced on behalf...
MacroGenics Announces Initiation of Phase 2/3 MAHOGANY Study of Margetuximab in Gastric or Gastroesophageal Junction Cancer
October 25, 2019 07:30 ET
|
MacroGenics, Inc.
Rockville, MD, Oct. 25, 2019 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal...
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Canada Goose, Meredith Corporation, MacroGenics, and ViewRay and Encourages Investors to Contact the Firm
October 23, 2019 19:09 ET
|
Bragar Eagel & Squire
NEW YORK, Oct. 23, 2019 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder law firm, reminds investors that class action lawsuits have been commenced on behalf...
MacroGenics Announces Second Interim Overall Survival Data from Phase 3 SOPHIA Study of Margetuximab in Patients with HER2-Positive Metastatic Breast Cancer
October 22, 2019 16:30 ET
|
MacroGenics, Inc.
ROCKVILLE, MD, Oct. 22, 2019 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal...